[Central hypothyroidism associated with bexarotene therapy].
We report the case of a patient with cutaneous T-cell lymphoma treated by bexaroten Targretin, a synthetic retinoid analog with specific affinity for retinoid X receptor. The treatment induced mixed hyperlipidemia and severe central hypothyroidism characterized by reduced TSH and thyroxine serum levels. Only the pituitary thyreotrope function was affected. Targretin therapy can be maintained. Adverse drug events may be managed by fenofibrate Lipanthyl for dyslipidemia and high dose L-thyroxin Lévothyrox requiring serum free thyroxin level measurement for central hypothyroidism.
Martin
C
C
Service de Biochimie Spécialisée, Unité d'hormonologie et de RIA.
Bach-Ngohou
K
K
Perrin
B
B
Masson
D
D
D016588:Anticarcinogenic Agents / Q000009:adverse effects*; D000077610:Bexarotene; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced; D007037:Hypothyroidism / Q000139:chemically induced*; D016399:Lymphoma, T-Cell / Q000188:drug therapy*; D008875:Middle Aged; D047488:Retinoid X Receptors / Q000819:agonists; D013764:Tetrahydronaphthalenes / Q000009:adverse effects*; D013960:Thyroid Function Tests; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000097:blood
D016588:Anticarcinogenic Agents; D047488:Retinoid X Receptors; D013764:Tetrahydronaphthalenes; D013972:Thyrotropin; D000077610:Bexarotene; D013974:Thyroxine